JPRN-UMIN000005969
Completed
N/A
Clinical trial aimed at new therapeutic strategy for HAM by prosultiamine treatment with oral administration - Oral prosultiamine treatment against HAM patients as new therapeutics
The Department of Molecular Microbiology and Immunology0 sites25 target enrollmentJuly 15, 2011
ConditionsHTLV-I associated myelopathy (HAM)
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- HTLV-I associated myelopathy (HAM)
- Sponsor
- The Department of Molecular Microbiology and Immunology
- Enrollment
- 25
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •HAM patients who do not approve the protocol
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Clinical trial aimed at new therapeutic approch against HAM patients by pentosan polysulphateHTLV-I associated myelopathy (HAM)JPRN-UMIN000004492Department of Molecular Microbilogy and Immunology15
Active, Not Recruiting
Phase 1
CRA-TBETick-borne encephalitisMedDRA version: 21.1Level: LLTClassification code: 10077096Term: Tick-borne encephalitis immunization Class: 10042613Therapeutic area: Diseases [C] - Virus Diseases [C02]CTIS2023-509575-16-00Vaestra Goetalandsregionen100
Recruiting
N/A
Study on navauppu mezhugu in dysmenorrhoeaCTRI/2017/06/008938Ayothidas pandithar hospital10
Completed
Phase 1
Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc DiseaseIntervertebral Disc DiseaseNCT01513694Red de Terapia Celular15
Active, Not Recruiting
Phase 2
Study on efficacy of herbal drugs in reducing viral load in HIV/AIDS patientsCTRI/2022/09/045548MVR Ayurveda medical college